Crystal structure of botulinum neurotoxin type A and implications for toxicity
- PMID: 9783750
- DOI: 10.1038/2338
Crystal structure of botulinum neurotoxin type A and implications for toxicity
Abstract
Botulinum neurotoxin type A (BoNT/A) is the potent disease agent in botulism, a potential biological weapon and an effective therapeutic drug for involuntary muscle disorders. The crystal structure of the entire 1,285 amino acid di-chain neurotoxin was determined at 3.3 A resolution. The structure reveals that the translocation domain contains a central pair of alpha-helices 105 A long and a approximately 50 residue loop or belt that wraps around the catalytic domain. This belt partially occludes a large channel leading to a buried, negative active site--a feature that calls for radically different inhibitor design strategies from those currently used. The fold of the translocation domain suggests a mechanism of pore formation different from other toxins. Lastly, the toxin appears as a hybrid of varied structural motifs and suggests a modular assembly of functional subunits to yield pathogenesis.
Similar articles
-
Sequence homology and structural analysis of the clostridial neurotoxins.J Mol Biol. 1999 Sep 3;291(5):1091-104. doi: 10.1006/jmbi.1999.2945. J Mol Biol. 1999. PMID: 10518945
-
Crystal structure and novel recognition motif of rho ADP-ribosylating C3 exoenzyme from Clostridium botulinum: structural insights for recognition specificity and catalysis.J Mol Biol. 2001 Jan 5;305(1):95-107. doi: 10.1006/jmbi.2000.4292. J Mol Biol. 2001. PMID: 11114250
-
Light chain of botulinum neurotoxin serotype A: structural resolution of a catalytic intermediate.Biochemistry. 2006 Jul 25;45(29):8903-11. doi: 10.1021/bi060786z. Biochemistry. 2006. PMID: 16846233
-
A structural perspective of the sequence variability within botulinum neurotoxin subtypes A1-A4.J Mol Biol. 2006 Sep 29;362(4):733-42. doi: 10.1016/j.jmb.2006.07.040. Epub 2006 Jul 27. J Mol Biol. 2006. PMID: 16938310
-
The use of small molecules to investigate molecular mechanisms and therapeutic targets for treatment of botulinum neurotoxin A intoxication.ACS Chem Biol. 2006 Jul 21;1(6):359-69. doi: 10.1021/cb600179d. ACS Chem Biol. 2006. PMID: 17163773 Review.
Cited by
-
Recent Developments in Engineering Non-Paralytic Botulinum Molecules for Therapeutic Applications.Toxins (Basel). 2024 Apr 3;16(4):175. doi: 10.3390/toxins16040175. Toxins (Basel). 2024. PMID: 38668600 Free PMC article. Review.
-
Structural basis for antiepileptic drugs and botulinum neurotoxin recognition of SV2A.Nat Commun. 2024 Apr 18;15(1):3027. doi: 10.1038/s41467-024-47322-4. Nat Commun. 2024. PMID: 38637505 Free PMC article.
-
Conformational Space of the Translocation Domain of Botulinum Toxin: Atomistic Modeling and Mesoscopic Description of the Coiled-Coil Helix Bundle.Int J Mol Sci. 2024 Feb 20;25(5):2481. doi: 10.3390/ijms25052481. Int J Mol Sci. 2024. PMID: 38473729 Free PMC article.
-
A DARPin promotes faster onset of botulinum neurotoxin A1 action.Nat Commun. 2023 Dec 18;14(1):8317. doi: 10.1038/s41467-023-44102-4. Nat Commun. 2023. PMID: 38110403 Free PMC article.
-
A human bispecific antibody neutralizes botulinum neurotoxin serotype A.Sci Rep. 2023 Nov 27;13(1):20806. doi: 10.1038/s41598-023-48008-5. Sci Rep. 2023. PMID: 38012220 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
- Actions
LinkOut - more resources
Other Literature Sources
Medical
Molecular Biology Databases